Cambridge Cognition’s Post

🔬 Have you signed up yet? Are you ready to delve even deeper into the realm of central nervous system (CNS) therapies? Our Chief Scientist, francesca cormack alongside Altasciences will explore the crucial stages of drug development for CNS-active compounds. Reserve your spot now: https://lnkd.in/eMRuh5Xc 💡 Don't miss out on what promises to be another illuminating webinar! Here's what's in store: - Unravelling the essential cognitive and pharmacodynamic tests vital for your new CNS-active drug. - Identifying the most pertinent and reliable populations for testing, ensuring the utmost precision in your research. - Harnessing cognitive and pharmacodynamic data adeptly for seamless drug development and strategic regulatory planning. Secure your spot today to glean invaluable insights from some of the foremost experts in CNS research. #CNS #webinar #digitalbiomarkers #cognitivetesting

1. atai Life Sciences shares are expected to rise due to Phase 2 and 3 trial data in 2025, according to Jefferies analysts. 2. Analysts maintained a 'Buy' rating on the stock with a price target of $5, suggesting a 242% upside. 3. Key data releases in mid-2025 include studies on BPL-003 and COMP360 for treatment-resistant depression. 4. atai has minority stakes in Beckley Psytech and COMPASS Pathways, both involved in these studies. 5. Additional data from five Phase 2 trials is anticipated in 2024 and 2025. 6. Expected results include atai’s ELE-01 trial by year-end and VLS-01 by the end of 2025. 7. Analysts believe psychedelics may play a significant role in treating difficult central nervous system disorders. 8. Concerns center around drug efficacy and management execution in clinical studies, with potential regulatory improvements under a new administration.

The conviction that #serendipity can be, if not systematized, at least harnessed for augmented scientific discovery, has fueled my (obviously nonlinear) professional trajectory. As we saw with Fleming's "accidental" discovery of penicillin, the #AHA moment does not happen in a vacuum: the mind needs to be ready for the discovery (or "pasteurized" for chance to favor you). While researching other examples of serendipitous drug discovery, I came across an article about systematizing serendipity for cardiovascular drug discovery. It does not fully deliver on its promise, but I can't resist sharing that it is published in AHA journals. In case you are wondering, AHA is the American Heart Association. https://lnkd.in/gWhy2fUS

❗️Announcement❗️   We're thrilled to introduce Mitchell Steiner, MD, FACS, Chief Executive Officer of Veru Inc., as the newest addition to our expert speaker faculty!   Unveil the full speaker faculty here - https://ter.li/of61al   Attendees are gearing up for a groundbreaking presentation on advancing enobosarm, an oral novel selective androgen receptor modulator, to avoid muscle loss and augment fat loss when combined with a glucagon-like peptide-1 receptor agonist drug for potentially higher quality weight loss.   Explore Mitchell's talk in more detail by downloading full agenda - https://ter.li/of61al   The 𝗚𝗟𝗣-𝟭-𝗕𝗮𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 is a truly unique forum, dedicated to advancing GLP-1s, while combatting muscle deterioration. Mitchell Steiner emphasizes that:   “𝘞𝘦 𝘩𝘢𝘷𝘦 𝘳𝘦𝘢𝘤𝘩𝘦𝘥 𝘢 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘣𝘢𝘵𝘵𝘭𝘦 𝘢𝘨𝘢𝘪𝘯𝘴𝘵 𝘰𝘣𝘦𝘴𝘪𝘵𝘺. 𝘎𝘓𝘗-1 𝘢𝘨𝘦𝘯𝘵𝘴 𝘢𝘳𝘦 𝘷𝘦𝘳𝘺 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘸𝘦𝘪𝘨𝘩𝘵 𝘭𝘰𝘴𝘴 𝘥𝘳𝘶𝘨𝘴, 𝘣𝘶𝘵 𝘮𝘶𝘴𝘤𝘭𝘦 𝘪𝘴 𝘴𝘢𝘤𝘳𝘪𝘧𝘪𝘤𝘦𝘥. 𝘛𝘩𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘯𝘦𝘹𝘵 𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘥𝘳𝘶𝘨𝘴 𝘴𝘩𝘰𝘶𝘭𝘥 𝘧𝘰𝘤𝘶𝘴 𝘰𝘯 𝘵𝘩𝘦 𝘲𝘶𝘢𝘭𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘸𝘦𝘪𝘨𝘩𝘵 𝘭𝘰𝘴𝘴, 𝘱𝘳𝘦𝘧𝘦𝘳𝘦𝘯𝘵𝘪𝘢𝘭𝘭𝘺 𝘳𝘦𝘮𝘰𝘷𝘪𝘯𝘨 𝘧𝘢𝘵 𝘸𝘩𝘪𝘭𝘦 𝘱𝘳𝘦𝘴𝘦𝘳𝘷𝘪𝘯𝘨 𝘮𝘶𝘴𝘤𝘭𝘦. 𝘛𝘩𝘦 𝘎𝘓𝘗-1-𝘉𝘢𝘴𝘦𝘥 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘚𝘶𝘮𝘮𝘪𝘵 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘴 𝘢 𝘧𝘰𝘳𝘶𝘮 𝘵𝘰 𝘢𝘥𝘷𝘢𝘯𝘤𝘦 𝘵𝘩𝘪𝘴 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺.” Will you be uniting with 𝟲𝟬+ 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 this May, all committed to 𝘀𝘁𝗮𝘆𝗶𝗻𝗴 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗰𝘂𝗿𝘃𝗲?   #GLP1BasedTherapeuticsSummit

Exploring the optimal timing and methodologies for cognitive and pharmacodynamic testing in first-in-human trials involving CNS-active compounds, our Chief Scientist francesca cormack will be exploring the critical stages of drug development for central nervous system therapies with our partners at Altasciences.   Topics include: _ Determining the necessary cognitive and pharmacodynamic tests for your new CNS-active drug. - Identifying the most relevant and valid populations for testing. - Leveraging cognitive and pharmacodynamic data for drug development and regulatory planning.   Whether you're a seasoned professional or new to the field, this webinar will equip you with the knowledge and strategies to enhance your research and development processes. Register now to secure your spot: https://lnkd.in/eg_Hkdc9   #DrugDevelopment #Clinicaltrials #CNS 

#ACROHighlights [Featured Product] 🚀 Harnessing Cardiac Organoids for Enhanced Drug Development 🌟 Drug-induced cardiotoxicity is a significant challenge in new drug development. Due to their physiological relevance and reproducibility, cardiac organoids derived from iPSCs are now a game-changer for high-throughput drug safety screening. At ACROBiosystems, we've developed cardiac organoids that accurately predict drug-induced cardiotoxicity. But we don't stop there! Our ongoing research also covers other organoid models, including brain, liver, and intestines, to offer comprehensive support for future clinical trials. Join us at the forefront of innovation in drug development! 💊✨ 🔗https://lnkd.in/gzPuS_xg #Biotech #DrugDevelopment #CardiacOrganoids #iPSCs #ClinicalTrials

Check out this great news from our portfolio company, Hope Medicine Inc! The company's monoclonal antibody drug, HMI-115, which holds global rights, has been granted Breakthrough Therapy Designation (BTD) by the CDE of the NMPA. This designation is for the treatment of moderate to severe pain associated with endometriosis. The CDE's recognition is based on promising interim results from an ongoing global Phase 2 clinical trial. This randomized, double-blind, placebo-controlled study includes 142 women with endometriosis across the US, Poland, and China, led by Peking Union Medical College Hospital in China. Among the 102 patients included in the interim analysis, HMI-115 showed significant improvement in endometriosis-related pain with a strong safety profile. Most patients reported normal menstruation, and there were no significant changes in bone density or hormone levels. #Biotech #Innovation #BreakthroughTherapy #Endometriosis #ClinicalResearch #WomensHealth #MedicalAdvancements #DrugDevelopment #GlobalHealth #NMPA #BTD #QimingPortfolio #QimingHealthcare

#ACROHighlights [Featured Product] 🚀 Harnessing Cardiac Organoids for Enhanced Drug Development 🌟 Drug-induced cardiotoxicity is a significant challenge in new drug development. Due to their physiological relevance and reproducibility, cardiac organoids derived from iPSCs are now a game-changer for high-throughput drug safety screening. At ACROBiosystems, we've developed cardiac organoids that accurately predict drug-induced cardiotoxicity. But we don't stop there! Our ongoing research also covers other organoid models, including brain, liver, and intestines, to offer comprehensive support for future clinical trials. Join us at the forefront of innovation in drug development! 💊✨ 🔗https://lnkd.in/gzPuS_xg #Biotech #DrugDevelopment #Organoids #iPSCs #AllianzBioinnovation #Research #India #ACROBiosystems

Data from the Phase III OCARINA II study shows the subcutaneous version of Roche's Ocrevus achieved near-complete suppression of relapses and brain lesions in relapsing or primary progressive multiple sclerosis. #pharma #biospace https://hubs.li/Q02tkbzx0

We are pleased to share positive interim results from our Phase 1 clinical study of VQ-101, a small molecule allosteric activator of GCase. In healthy volunteers in Phase 1a, VQ-101 demonstrated good tolerability, robust lysosomal GCase activation, and pharmacokinetics consistent with once daily dosing. The study, conducted at Centre for Human Drug Research, has advanced to the Phase 1b portion in patients with Parkinson’s disease. https://lnkd.in/eqRzbQct